je.st
news
Tag: vivus
Vivus - Flat Qsymia Scripts Point To Needed Shift
2015-03-02 21:52:57| Biotech - Topix.net
It is no secret that the Vivus's anti-obesity pill Qsymia have been pretty flat for over a year. If a flat sales trajectory is not troubling enough, the fact that Contrave from Orexigen is about to overtake Qsymia in just about 20 or 21 weeks should be a clear signal that a change is needed.
5-year lows: Vivus, Synta Pharmaceuticals Inc, MVC Capital Inc, and Kemet Corp.
2015-02-09 06:35:48| Semiconductors - Topix.net
According to GuruFocus list of 5-year lows , these Guru stocks have reached their 5-year lows: Vivus, Synta Pharmaceuticals Inc, MVC Capital Inc, and Kemet Corp. Vivus Reached $2.50 The prices of Vivus shares have declined to $2.50, which is only 3.6% above the 5-year low of $2.41. It is now 92.3% off the 5-year high of $31.21.
Tags: capital
corp
pharmaceuticals
lows
Vivus: Qsymia Sales Dip - Is A Lower Price Needed?
2015-02-08 09:08:40| Biotech - Topix.net
Vivus investors have seen Qsymia scripts remain in a pretty tight channel for over 15 months. While the sales have remained fairly steady, the arrival of a new competitor could have shifted the market in such a way that Vivus will have little choice but to respond.
Tags: price
sales
needed
lower
Bearish Movers: VIVUS, Inc. (NASDAQ:VVUS), First Solar, Inc....
2013-11-12 18:44:04| Appliances - Topix.net
StockMarketIntel.com issues a special report on the following stocks: VIVUS, Inc. , First Solar, Inc. , Eco-Tek Group Inc , Electrolux AB VIVUS, Inc. declined -0.99% recently, while trading on 291,933 shares at the price of $9.00.
Tags: inc
solar
movers
bearish
Auxilium Licenses Vivus ED Drug in $300M Deal
2013-10-12 03:51:34| Biotech - Topix.net
Auxilium Pharmaceuticals will get the right to sell Vivus' impotence drug Stendra in the U.S. and Canada as part of a deal between the two companies that could be worth more than $300 million.